K.I. Utesheva, T.T. Valiev, K.I. Kirgizov, S.R. Varfolomeeva
N.N. Blokhin National Medical Research Centre of Oncology, Moscow
Utesheva Kristina I. ― pediatric oncologist of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) №1 of the Research Institute of Pediatric Oncology and Hematology at N.N. Blokhin National Medical Research Center of Oncology
23 Kashirskoe highway, Moscow, 115478, Russian Federation, e-mail: email@example.com, ORCID ID: 0000000212682171
Abstract. Hodgkin lymphoma (HL) is one of the most curable lymphoproliferative disease, in particular because of high-effective, but at the same time, toxic treatment regimens. Inspite of the favorable prognosis, the risk of relapse or refractory (r/r) HL is 10-20%. A new drugs such as brentuximab vedotin (BV) and immune checkpoint inhibitors (nivolumab, pembrolizumab), which are using for r/r HL during the last 10 years, have high antitumor activity and increase a many-year relapse-free survival up to 59%. For decreasing the toxicity rate of standard first-line schemes for HL in children, it is collecting a clinical experience in BV in patients with primary diagnosed HL.
Another therapeutic approaches for r/r HL are cell technologies, including autologous and allogenic stem cell transplantation (auto- and allo-SCT), the use of CAR-T-cells. A complex approach in treatment hold out the promise of the same high treatment results in r/r HL as in primary diagnosed HL.
In the current issue it is presented a modern treatment strategies for HL in children, and a new drugs for r/r HL.
Key words: Hodgkin lymphoma, immune checkpoint inhibitors, targeted therapy, PD-1, PD-L1, CD30, brentuximab vedotin.